These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Refuerzo JS; Garg A; Rech B; Ramin SM; Vidaeff A; Blackwell SC Am J Perinatol; 2012 May; 29(5):335-8. PubMed ID: 22094918 [TBL] [Abstract][Full Text] [Related]
28. New drugs for type 2 diabetes mellitus: what is their place in therapy? Krentz AJ; Patel MB; Bailey CJ Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. Thompson PL; Davis TME Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704 [TBL] [Abstract][Full Text] [Related]
31. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience. Deol H; Lekkakou L; Viswanath AK; Pappachan JM Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231 [TBL] [Abstract][Full Text] [Related]
32. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Healy SJ; Nagaraja HN; Alwan D; Dungan KM Endocrine; 2017 Apr; 56(1):90-97. PubMed ID: 28058528 [TBL] [Abstract][Full Text] [Related]
33. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i. Lanzinger S; Schmid SM; Welp R; Zimmermann A; Fasching P; Wagner S; Holl RW Diabetes Res Clin Pract; 2018 Dec; 146():162-171. PubMed ID: 30367902 [TBL] [Abstract][Full Text] [Related]
34. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070 [TBL] [Abstract][Full Text] [Related]
35. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Campbell RK Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843 [TBL] [Abstract][Full Text] [Related]
36. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938 [TBL] [Abstract][Full Text] [Related]
37. New developments in diabetes management: medications of the 21st century. Fonseca VA Clin Ther; 2014 Apr; 36(4):477-84. PubMed ID: 24594068 [TBL] [Abstract][Full Text] [Related]
38. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. Basile JN Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810 [TBL] [Abstract][Full Text] [Related]
39. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918 [TBL] [Abstract][Full Text] [Related]
40. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Singh AK; Singh R Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]